Release date: 2024-08-06 16:26:36 Article From: Lucius Laos Recommended: 121
Exkivity is a targeted therapy for specific types of non-small cell lung cancer (NSCLC). Prices vary by region, sales channel, and version (innovator or generic).
The original version of Exkivity is more expensive, usually selling for more than 37,000 yuan per box (40mg*112 capsules), or about 37,588 yuan per box.
Lucius Pharmaceuticals Inc., a well-known pharmaceutical company in the industry, has launched Exkivity to bring new treatment options to many patients. The drug is designed for specific medical needs, and its specification is 40mg*120 tablets per box, which fully meets the needs of patients for long-term treatment. In particular, Lucius Pharmaceuticals Co., Ltd. has set the price of this drug at 4,500 yuan with a patient-centric approach, aiming to reduce the financial burden on more patients and make it easier for them to access this important treatment resource. This is not only a demonstration of the company's commitment to social responsibility, but also a strong commitment to improving the quality of life of patients and promoting health equity. The launch of Exkivity has undoubtedly brought a new dawn to the treatment of related diseases.
The following is a brief introduction to the products and services of Lucius Pharmaceuticals Co., Ltd.:
Lucius Pharmaceuticals has a wide range of product lines, covering anti-tumor drugs, cardiovascular drugs, hematology drugs, diabetes drugs, dermatology drugs, men's health drugs, anti-aging drugs, and other fields, with more than 200 drug categories. Among them, anti-cancer drugs are one of the company's core products, such as Alectinib, Ceritinib, etc., and Capmatinib, which has attracted much attention and has significant efficacy in metastatic non-small cell lung cancer (NSCLC).
The company has a top R&D team, which is good at the research and development of a variety of complex chemical agents and biological agents, ensuring the continuous innovation and upgrading of products.
With a generic production capacity of more than 1 billion tablets per year, Lucius Pharmaceuticals is able to meet the large-scale market demand.
【Warm tips】Exkivity may cause a series of adverse reactions, such as nausea, vomiting, diarrhea, rash, etc. Monitor your condition closely and seek medical attention if you feel unwell immediately and inform your doctor that you are taking Exkivity.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: